Migraine is more than a headache. It often lasts longer (up to 72 hours) and is more severe. There are many symptoms of migraine, including nausea, vomiting, and sensitivity to light and sound. The ...

Topamax (topiramate) may cause various side effects, including constipation, in some people. While not a common issue, knowing how to manage constipation and related side effects can help you continue ...

Topamax, while approved for seizure disorders and migraine prevention, is sometimes used off-label to treat depression, though its effectiveness for this purpose lacks extensive clinical support.

Topiramate — commonly known as topamax in Canada and the United States — was approved for use as a treatment for epilepsy in 1995. But in 2004, the American Food and Drug Administration approved the ...

The epilepsy and migraine prevention drug Topamax has been linked to an increased risk of birth defects in babies born to epilepsy patients who took it during pregnancy , a small study shows. In a ...

Although Topamax is not FDA approved for weight loss, doctors may prescribe the drug off-label. Studies show that people taking Topamax for 24 weeks lose about 4.5% to 6.5% of body weight. Topamax may ...

Living well with migraine isn’t just about taking medication when you have an attack. Preventive treatments are medications you use on a regular schedule to reduce the number and severity of your ...

How Does Topirmate for Weight Loss Work? This article was reviewed by Mike Bohl, MD, MBA, MPH, MS, ALM. Topiramate, also sold under the brand name Topamax, is a drug approved by the U.S. Food and Drug ...

Two subsidiaries of pharmaceutical giant Johnson & Johnson have agreed to pay more than $81 million stemming from allegedly illegal promotion of the epilepsy drug Topamax for psychiatric uses, the ...

Discover the safety and effectiveness of Topamax (Topiramate) for weight loss as we delve into reviews and off-label use. Topamax (topiramate) is sometimes used off-label for weight loss despite not ...

In the second off-label marketing settlement this week, two Johnson & Johnson subsidiaries have agreed to pay $81 million to wrap up a probe of their Topamax promotions. The deal involves a $6.1 ...

WASHINGTON -- Two subsidiaries of pharmaceutical giant Johnson & Johnson have agreed to pay more than $81 million stemming from allegedly illegal promotion of the epilepsy drug Topamax for psychiatric ...